We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Lung Adenocarcinoma Genomic Features Differ in East Asians, Europeans

By LabMedica International staff writers
Posted on 18 Feb 2020
Print article
Image: Histopathology of Lung adenocarcinoma (Photo courtesy of Nikon).
Image: Histopathology of Lung adenocarcinoma (Photo courtesy of Nikon).
Lung adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC). Lung adenocarcinoma is categorized as such by how the cancer cells look under a microscope. Lung adenocarcinoma starts in glandular cells, which secrete substances such as mucus, and tends to develop in smaller airways, such as alveoli.

Lung cancer is the world’s leading cause of cancer death and shows strong ancestry disparities. Lung adenocarcinoma is a common cancer and leads to more than one million deaths each year. A new analysis has found that lung tumors isolated from patients of East Asian ancestry have a less complex genomic architecture than tumors from European patients.

Scientists from the Genome Institute of Singapore (A*STAR, Singapore) and their associates characterized the genomic landscape of lung cancer among East Asians, generating a genomic and transcriptomic dataset encompassing more than 300 lung cancer patients of Chinese ancestry. They sequenced the exomes and transcriptomes of 213 Chinese lung adenocarcinoma patients from Singapore and combined that dataset with previously published whole-exome sequencing data on 92 Chinese patients from another cohort. By comparing the genomic and transcriptomic data from these 305 individuals to that of 249 lung adenocarcinoma patients of European ancestry from The Cancer Genome Atlas, they uncovered differences in tumor mutational burden and driver genes between the groups.

The team reported that overall, East Asian patients' tumors had fewer genomic alterations, with a median tumor mutational burden of 2.04 per Mb, as compared to a median 5.08 per Mb among European patients. While this burden was influenced by patients' smoking status, even among smokers, East Asian patients had a lower median tumor mutational burden than European patients. At the same time, the number and nature of driver mutations differed between tumors from East Asian and European patients. In East Asian patients, alterations affecting the EGFR, TP53, and KRAS genes were the most common driver mutations and nonsmokers had an average 2.08 driver mutations, as compared to an average 2.65 driver mutations among European nonsmokers. Additionally, East Asian patients had fewer copy number variations.

By analyzing the transcriptomic profiles of the tumor samples, the scientists teased out three different lung cancer sub-clusters. Two of these were similar to the terminal respiratory unit (TRU) and proximal inflammatory sub-clusters previously found in European patients, but the third was specific to East Asians. That sub-cluster, dubbed TRU-I, was marked by the upregulation of inflammation-associated genes and increased immune infiltration. This phenotype could help identify patients who might be more likely to benefit from immunotherapy or immune checkpoint blockade treatment.

While they found that patients' clinical features could predict their outcomes, they noted that genomic features could also predict patient survival. These predictions were more accurate for East Asian than European patients, which they attributed to their more stable tumor genomes. The authors concluded that their study elucidated a comprehensive genomic landscape of East Asian ancestry lung adenocarcinomas and highlighted important ancestry differences between the two cohorts. The study was published on February 3, 2020 in the Nature Genetics.

Related Links:
Genome Institute of Singapore

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.